Barclays Issues Positive Forecast for Teva Pharmaceutical Industries (NYSE:TEVA) Stock Price

Teva Pharmaceutical Industries (NYSE:TEVA) had its price target upped by Barclays from $25.00 to $28.00 in a report published on Wednesday,Benzinga reports. The firm currently has an overweight rating on the stock.

Several other research firms have also recently commented on TEVA. StockNews.com raised Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Thursday, October 17th. UBS Group increased their price target on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a “buy” rating in a research report on Tuesday, September 3rd. Finally, JPMorgan Chase & Co. raised their target price on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a research report on Monday, October 21st. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $20.88.

Teva Pharmaceutical Industries Stock Performance

TEVA stock traded up $0.19 during midday trading on Wednesday, hitting $21.39. 616,161 shares of the company traded hands, compared to its average volume of 9,373,116. The business has a 50 day simple moving average of $17.61 and a 200-day simple moving average of $17.45. The company has a quick ratio of 0.61, a current ratio of 0.89 and a debt-to-equity ratio of 2.57. Teva Pharmaceutical Industries has a twelve month low of $10.34 and a twelve month high of $21.98. The stock has a market capitalization of $24.23 billion, a price-to-earnings ratio of -25.16, a price-to-earnings-growth ratio of 0.99 and a beta of 0.79.

Insider Transactions at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, EVP Christine Fox sold 19,388 shares of the firm’s stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $16.87, for a total value of $327,075.56. Following the completion of the sale, the executive vice president now owns 44,104 shares in the company, valued at approximately $744,034.48. This trade represents a 30.54 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 0.55% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of TEVA. Thrivent Financial for Lutherans boosted its holdings in Teva Pharmaceutical Industries by 21.8% in the third quarter. Thrivent Financial for Lutherans now owns 224,511 shares of the company’s stock valued at $4,046,000 after acquiring an additional 40,218 shares during the last quarter. Sio Capital Management LLC bought a new position in shares of Teva Pharmaceutical Industries in the 3rd quarter valued at about $24,314,000. TCW Group Inc. acquired a new stake in shares of Teva Pharmaceutical Industries during the 3rd quarter worth approximately $1,286,000. Two Sigma Advisers LP lifted its holdings in Teva Pharmaceutical Industries by 15.3% in the third quarter. Two Sigma Advisers LP now owns 1,034,500 shares of the company’s stock valued at $18,642,000 after buying an additional 137,000 shares during the period. Finally, Pitcairn Co. bought a new position in Teva Pharmaceutical Industries in the third quarter valued at approximately $947,000. Institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.